Literature DB >> 11059649

Screening for germline p53 mutations in pediatric and adult patients of high-risk groups in Poland.

L Fiszer-Maliszewska1, J Czernik, K Sawicz-Birkowska, D Perek, M Kozera, B Wojciechowska, B Kazanowska, P Hudziec, E Kilar.   

Abstract

Germline mutations of the p53 gene lead to cell transformation in various tissues. Such a complex cancer phenotype makes it difficult to recognize the carriers of the defective allele. Several studies undertaken to identify high-risk groups found germline p53 mutations in familial cancer aggregations and in patients with multiple tumors. We screened 189 pediatric and 48 adult patients. The high-risk groups comprised 41 patients with a family history of cancer and 35 with multiple neoplasms. Furthermore, 124 tumors were screened for somatic mutations. p53 exons 2 to 11 were analyzed by polymerase chain reaction and single strand conformation polymorphism (PCR-SSCP) followed by direct sequencing of abnormal DNA fragments. No germline p53 mutations were found and somatic mutations were detected in 5 of 59 sarcomas, globally, in 8 of 124 tumors. In conclusion, in Poland, p53 alterations do not seem very important for the predisposition to malignancy and development of sarcomas.

Entities:  

Mesh:

Year:  2000        PMID: 11059649

Source DB:  PubMed          Journal:  Arch Immunol Ther Exp (Warsz)        ISSN: 0004-069X            Impact factor:   4.291


  2 in total

1.  P53 mutations in urinary bladder cancer patients from Central Poland.

Authors:  Edyta Borkowska; Aleksandra Binka-Kowalska; Maria Constantinou; Agnieszka Nawrocka; Józef Matych; Bogdan Kałuzewski
Journal:  J Appl Genet       Date:  2007       Impact factor: 3.240

2.  p53 Tetramerization domain mutations: germline R342X and R342P, and somatic R337G identified in pediatric patients with Li-Fraumeni syndrome and a child with adrenocortical carcinoma.

Authors:  Lucja Fiszer-Maliszewska; Bernarda Kazanowska; Joanna Padzik
Journal:  Fam Cancer       Date:  2009       Impact factor: 2.375

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.